Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biotech Firms In China, India, Brazil Thriving; Time For Big Pharma To Step In?

This article was originally published in PharmAsia News

Executive Summary

By addressing local health challenges and leveraging cost-efficiency in research and development, biotech firms in emerging China, India, Brazil and South Africa (BRISA) are growing faster than ever. Global drug makers can benefit in these markets by sharing expertise and forming collaborations with these companies, say health researchers Rahim Razaie and Peter Singer at the Mclaughlin-Rotman Center for Global Health at the University of Toronto

You may also be interested in...



With More Vaccines For Low-Income Countries In Mind, Merck Signs JV With Wellcome Trust; India To Be Research And Manufacturing Hub

MUMBAI - New opportunities like preventive vaccines for developing countries are throwing up newer alliances between disparate stakeholders. In one such deal, New Jersey-headquartered Merck has formed a first-of-its-kind equal stake collaboration with Wellcome Trust of the United Kingdom to work on research and development of vaccines that can prevent diseases mainly in low-income countries

Sanofi Beats GSK To Buy Merieux Alliance's Stake In India's Shantha Biotech; Move Aimed At Stronger Vaccines Business In Emerging Markets

MUMBAI - In a takeover battle that lasted several months, drug maker Sanofi-Aventis emerged winner beating global rival GlaxoSmithKline among others to lap up a majority equity stake in India's Shantha Biotechnics from fellow French pharmaceutical firm Merieux Alliance. Shantha Biotechnics was valued at €550 million ($750 million) on expected sales of €90 million for the current financial year

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

SC075967

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel